10-K: Clene Inc. Advances ALS Drug Towards Accelerated FDA Approval

Clene Inc. reports strong clinical data for its lead drug candidate CNM-Au8 in ALS, paving the way for an accelerated FDA approval pathway by mid-2026, despite ongoing financial challenges.

Summary

• Clene Inc. is a clinical-stage pharmaceutical company focused on developing novel clean-surfaced nanotechnology (CSN) therapeutics for neurodegenerative diseases like ALS, MS, and PD.
• The lead drug candidate, CNM-Au8, is a catalytically-active gold nanocrystal suspension designed to enhance energetic metabolism, reduce oxidative stress, and promote protein homeostasis in diseased cells.
• For Amyotrophic Lateral Sclerosis (ALS), CNM-Au8 has demonstrated statistically significant survival benefits and reductions in neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) biomarkers across multiple clinical trials and expanded access programs.
• A Type C in-person meeting with the FDA is expected in Q1 2026 to discuss the data and confirm the ability to file a New Drug Application (NDA) for ALS under an accelerated approval pathway by the end of June 2026.
• A Phase 3 RESTORE-ALS trial is planned to commence in the second half of 2026, contingent on funding, to serve as a post-approval confirmatory study.
• For Multiple Sclerosis (MS), CNM-Au8 showed significant increases in the brain NAD+/NADH ratio in the REPAIR-MS trial and sustained improvements in low contrast letter acuity (LCLA) and cognitive processing speed (SDMT) in the VISIONARY-MS long-term extension.
• For Parkinson's Disease (PD), preclinical data demonstrated CNM-Au8 improved mitochondrial health, reduced inflammation, and restored cellular metabolism in neuron models.
• The company reported a net loss of $26.2 million for the year ended December 31, 2025, an improvement from $39.4 million in 2024, with an accumulated deficit of $308.3 million.
• Cash and cash equivalents were $5.2 million as of December 31, 2025, down from $12.2 million in 2024, and net cash used in operating activities was $18.5 million.
• The company has identified material weaknesses in its internal control over financial reporting related to its control environment, account reconciliations, manual journal entries, and IT general controls.
• Substantial doubt exists about the company's ability to continue as a going concern within the next twelve months without additional financing.
• The company received a four-year NIH grant totaling $45.1 million to support the ACT-EAP for ALS, with subawards to Clene Inc. potentially reaching $30.9 million by August 31, 2027.
• Clene Inc. generated $10.6 million in gross proceeds from its equity distribution agreement in 2025 and $1.5 million from senior secured convertible promissory notes in 2025. Subsequent to year-end, an additional $6.0 million was raised from a public equity offering in January 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing with a moderately positive sentiment. The clinical data for CNM-Au8, particularly in ALS, is consistently strong and points towards a clear regulatory path for accelerated approval, addressing a high unmet medical need. However, the company's significant financial challenges and 'going concern' warning introduce substantial risk, necessitating careful monitoring of future capital raises and operational efficiency.

Positives

• CNM-Au8 demonstrated statistically significant survival benefits in ALS patients, with a cross-over adjusted median survival difference of 19.3 months in RESCUE-ALS OLE and a 75% decreased risk of long-term all-cause mortality (HR: 0.252, p<0.001).
• Pooled analyses from HEALEY ALS Platform Trial and RESCUE-ALS showed a statistically significant 59% decreased risk of death for CNM-Au8 30 mg compared to PRO-ACT matched placebo patients (HR: 0.406, p=0.004).
• Statistically significant reductions in plasma neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) biomarkers were observed in ALS trials, with NfL and GFAP decline associated with an 80% reduction in the risk of death (Cox HR: 0.191, p=0.0210).
• Exploratory findings identified Insulin-like Growth Factor Binding Protein 7 (IGFBP7) decline as strongly associated with improved survival in ALS, showing a 78% mortality risk reduction (HR: 0.22, p=0.012).
• CNM-Au8 demonstrated target engagement in the brain by significantly increasing the NAD+/NADH ratio in MS and PD patients (REPAIR-MS/PD combined: +8.65%, p=0.0006).
• Clinically relevant and sustained improvements in low contrast letter acuity (LCLA) and cognitive processing speed (SDMT) were observed in MS patients in the VISIONARY-MS trial and its long-term extension, supported by objective MRI DTI and mf-VEP biomarkers.
• Preclinical data for Parkinson's disease showed CNM-Au8 improved mitochondrial health, reduced inflammation, restored cellular metabolism, and normalized dysregulated gene expression in dopaminergic neuron models.
• CNM-Au8 has a favorable safety and tolerability profile with over 1,100 participant-years of exposure and no significant safety concerns or serious adverse events identified.
• The FDA has provided guidance and granted a Type C in-person meeting in Q1 2026 to discuss the data and confirm the accelerated approval pathway for ALS, indicating a clear regulatory path forward.
• The company's net loss decreased from $39.4 million in 2024 to $26.2 million in 2025, and net cash used in operating activities decreased from $21.3 million to $18.5 million, indicating some financial improvement.
• Secured a four-year NIH grant totaling $45.1 million to support the ACT-EAP for ALS, with subawards to Clene Inc. up to $30.9 million, providing significant non-dilutive funding for clinical activities.

Negatives

• The company has incurred significant net losses and negative cash flows from operations since inception, with an accumulated deficit of $308.3 million as of December 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern within the next twelve months without obtaining additional financing.
• Cash and cash equivalents decreased from $12.2 million in 2024 to $5.2 million in 2025.
• The RESCUE-ALS trial did not meet its primary or secondary endpoints, although efficacy signals were observed in pre-specified analyses.
• The HEALEY ALS Platform Trial's primary endpoint of rate of change in ALSFRS-R adjusted for mortality was not statistically significant at 24 weeks.
• The VISIONARY-MS trial ended prematurely in July 2022 due to operational challenges related to the COVID-19 pandemic, limiting enrollment.
• The FDA initially determined that initial NfL biomarker reduction findings from Phase 2 ALS trials were insufficient to support accelerated approval in Q4 2023, requiring additional data and analyses.
• The company identified material weaknesses in its internal control over financial reporting, which could affect the accuracy and timeliness of financial reporting.
• Revenue from product and royalty sales of dietary supplements is immaterial and not expected to be a significant contributor to future revenue.

Risks

• Substantial dependence on the successful commercialization of drug candidates, which may fail to materialize or experience significant delays.
• Inability to become profitable when expected, or at all, due to reliance on research and development and lack of commercial sales revenue.
• Failure to obtain sufficient funding to finance operations, which could force delays, reductions, or termination of drug development or commercialization efforts.
• Unstable market and economic conditions may adversely affect business, financial condition, results of operations, and prospects.
• Limited operating history makes it difficult to evaluate current business and predict future performance.
• Potential difficulties in managing growth and expanding operations successfully.
• Changes in government regulation or practices relating to the pharmaceutical and biotechnology industries, including potential healthcare reform, could decrease demand or hinder regulatory approvals.
• Internal computer systems or those of third-party contractors may fail or suffer security breaches, leading to disruptions, data loss, and reputational damage.
• Self-manufacturing of drug candidates could lead to unanticipated delays, expenses, or inability to scale production.
• Delays in completing and receiving regulatory approvals for manufacturing facilities could harm business.
• Damage to, destruction of, or interruption of production at manufacturing facilities would negatively affect business and prospects.
• Significant or sustained inflation could adversely affect business, financial condition, and results of operations.
• Dependence on ability to retain key executives and attract, train, retain, develop, and motivate qualified and highly skilled personnel.
• Impact of health epidemics and pandemics on business and operations, including supply chain disruptions and clinical trial delays.
• Significant uncertainty associated with drug candidates and their viability as commercial products, including regulatory classification and long-term effects of accumulation.
• Lack of prior regulatory approval for a drug candidate, which may lead to inability or delays in obtaining approval.
• Lengthy and expensive preclinical and clinical development processes with uncertain outcomes.
• Clinical trials may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or produce positive results.
• Difficulties enrolling patients in clinical trials could lead to delays.
• Disruptions to the normal functioning of the FDA and comparable foreign regulatory authorities could negatively impact business.
• Favorable designations (e.g., Fast Track, Breakthrough Therapy) may not be granted or may be withdrawn.
• Orphan drug designation for ALS may not realize full benefits or be withdrawn.
• Ongoing or additional regulatory obligations and review post-approval may result in significant additional expense and penalties for non-compliance.
• Approved drugs may become subject to national or other third-party reimbursement practices or unfavorable pricing regulations.
• Failure of approved drugs to achieve market acceptance by physicians, patients, third-party payors, and others.
• Undesirable side effects or perceived side effects of drugs could lead to delays, denial of approval, or limitations on commercial profile.
• Adverse drug reactions and negative results from off-label use could harm business reputation and expose to liability.
• Lack of experience in launching and marketing drugs.
• Substantial competition from other pharmaceutical and biotechnology companies.
• Exposure to anti-kickback, false claims, physician payment transparency, privacy and security, fraud and abuse laws.
• Difficulties from changes to current regulations and future legislation, including healthcare reform efforts.
• Failure to perform proper quality control and quality assurance.
• Risks associated with licensing of commercialization rights or other forms of collaboration worldwide.
• Dependence on raw materials from a limited number of suppliers, with risks of supply decrease, cost increase, or quality issues.
• Inability to obtain and maintain sufficient patent protection or broad scope for drug candidates.
• Intellectual property discovered through government-funded programs may be subject to federal regulations like march-in rights.
• Involvement in lawsuits to protect or enforce intellectual property, which could be expensive and time-consuming.
• Being sued for infringing the intellectual property rights of third parties.
• Noncompliance with procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies.
• Failure to obtain patent term extension and data exclusivity for drug candidates.
• Changes in patent law could diminish the value of patents.
• Inability to protect the confidentiality of trade secrets.
• Claims that employees have wrongfully used or disclosed alleged trade secrets of their former employers.
• Intellectual property rights may not protect from all potential threats to competitive advantages.
• Significant expenses and administrative burdens as a public company.
• Smaller reporting company status may make common stock less attractive to investors.
• Provisions in amended and restated certificate of incorporation and bylaws could make a merger, tender offer, or proxy contest difficult.
• Future offerings of debt or equity securities may dilute economic and voting rights of existing stockholders or adversely affect market price.
• Inability to comply with the continued listing requirements of Nasdaq.
• Volatility in the price of common stock.
• SEC regulations limit the amount of funds that can be raised during any 12-month period pursuant to shelf registration statement on Form S-3 (Baby Shelf Rule).

Future Outlook

Clene Inc. plans to submit a New Drug Application (NDA) for CNM-Au8 for ALS under an accelerated approval pathway by the end of June 2026, with meeting minutes from the FDA expected early in Q2 2026. A Phase 3 RESTORE-ALS trial is planned to commence in the second half of 2026, contingent on funding, to serve as a post-approval confirmatory study. For MS, the company will work with regulatory authorities and experts to determine the path to advance CNM-Au8 into Phase 3, focusing on cognition improvement. Development of CNM-AgZn17 for wound healing is planned to advance to GLP dermal toxicity studies, followed by an IND filing and Phase 1 human safety study, contingent on capital availability. The company intends to retain all available funds and future earnings to fund business growth and development, and does not intend to pay cash dividends in the foreseeable future.

Management Comments

• We believe that our patent-protected, proprietary position affords us the potential to develop a broad and deep pipeline of novel CSN therapeutics to address a range of diseases with high impact on human health.
• We believe we have established ourselves as an industry leader in the development of therapeutic catalytic nanocrystals.
• We believe CNM-Au8 is the only drug candidate in development with these unique catalytic mechanisms using gold nanocrystals.
• We believe CNM-Au8 has the potential to be a first-in-class disease modifying nanotherapeutic for ALS, MS, and PD.
• We believe our current production capabilities are sufficient to meet our needs for both research and development and to supply our ongoing and planned clinical trials and EAPs, and we believe our processes can be scaled to achieve early commercially viable quantities.
• We believe that our remediation plan will be sufficient to remediate the identified material weaknesses and strengthen our internal control over financial reporting.

Industry Context

StockSavvy.ai notes that the neurodegenerative disease space, including ALS, MS, and PD, has historically been challenging for traditional small molecule and biologic drug development, with limited disease-modifying therapies available. The focus on energetic failure as a key contributor to these diseases, and the development of multimodal nanotherapeutics like CNM-Au8, represents a novel approach. The use of NfL as a surrogate biomarker for FDA approval, as seen with tofersen for SOD1-ALS, provides a precedent for Clene Inc.'s strategy. The observed improvements in LCLA and SDMT in MS patients are particularly noteworthy, as these measures typically show long-term declines in MS patients according to data from the MS Outcome Assessments Consortium (MSOAC), suggesting a potential differentiation for CNM-Au8.

Comparison to Industry Standards

• CNM-Au8 demonstrated clearly superior human motor neuron protection compared to riluzole in an iPSC model of ALS.
• Oral delivery of CNM-Au8 to ALS model mice extended median lifespan by over three times the lifespan extension attributed to edaravone or riluzole treatment reported in the literature.
• CNM-Au8 exhibits higher catalytic activity for directly oxidizing NADH into NAD+ than any other commercially available gold nanoparticle tested.
• CNM-Au8 is in a different class from standard antioxidants because, to our knowledge, no other antioxidant demonstrates catalytic ability to increase energetic metabolites NAD+ and ATP, while independently catalytically decreasing reactive oxygen species (ROS).
• The increasing mean improvements observed across the VISIONARY-MS trial population (CNM-Au8 and placebo) for LCLA, SDMT, 9HPT, and T25FW are notable when contrasted with the anticipated long-term decline reported in publications from the MSOAC data for RMS patients.
• CNM-Au8 did not demonstrate evidence of toxicity toward PD dopaminergic cells at all tested doses, a finding consistent with the clinical observation that CNM-Au8 treatment in humans in ALS and MS has not demonstrated significant safety concerns.

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• Exclusive supply and license agreements with 4Life Research LLC (a stockholder, debt holder, and related party) for dietary supplement products (Zinc Factor and Gold Factor).
• Sales of Zinc Factor and Gold Factor to 4Life Research LLC generated $198,000 in product and royalty revenue from related parties in 2025.
• Senior Secured Convertible Promissory Notes (2024 SSCP Notes) totaling $10.0 million were sold to related parties, including an entity controlled by a board member, 4Life Research LLC, and an entity controlled by the chairman of 4Life who is also a subsidiary board member.

Stakeholder Impact

• Shareholders face potential dilution from future equity financings and stock price volatility due to the company's early stage and financial condition.
• Patients with ALS, MS, and PD could benefit from new disease-modifying nanotherapeutic options if CNM-Au8 successfully gains regulatory approval.
• Employees may be affected by cost-saving initiatives, including reductions in compensation and staff position eliminations, as the company manages its liquidity.
• Creditors, particularly holders of the Senior Secured Convertible Promissory Notes, are exposed to the company's 'going concern' risk and the requirement to maintain minimum cash balances.
• Suppliers of critical raw materials face risks related to the company's dependence on a limited number of sources and potential disruptions in the supply chain.

Next Steps

• Attend a Type C in-person meeting with the FDA in Q1 2026 to discuss biomarker data and confirm the ability to file an NDA for ALS under an accelerated approval pathway.
• Expect meeting minutes from the FDA early in Q2 2026 regarding the ALS accelerated approval pathway.
• Submit an NDA for ALS under an accelerated approval pathway by the end of June 2026.
• Commence the planned Phase 3 RESTORE-ALS trial in the second half of 2026, contingent on funding, to serve as the post-approval confirmatory study.
• Work closely with regulatory health authorities (FDA, EMA, etc.), MS experts, and patient representatives to determine the proper path to advance CNM-Au8 into Phase 3 for MS, focusing on cognition improvement.
• Complete a standard toxicology program in animals for CNM-AgZn17 to demonstrate safety for first-in-human dosing studies.
• Anticipate filing an IND with the FDA and subsequently initiating a standard Phase 1 dermal first-in-human safety study with CNM-AgZn17, subject to regulatory filings and capital availability.
• Continue the innovation of novel catalytically-active nanocrystals and ionic suspensions of metallic transition elements.
• Expand manufacturing capacity by developing the Elkton Facility, contingent upon successful future commercialization and funding.
• On or after January 1, 2027, the company will be permitted to sell Licensed Products through third-party retail outlets or via its own websites, as per the Amended 4Life Agreements.

Key Dates

Recommendation

Despite significant financial challenges and a 'going concern' warning, the clinical data for CNM-Au8, particularly in ALS, is compelling and consistently positive across multiple trials and biomarkers. The clear regulatory pathway towards an accelerated approval NDA submission by mid-2026, supported by strong survival and biomarker data, presents a substantial upside catalyst. The potential for a first-in-class disease-modifying nanotherapeutic in high-unmet-need neurodegenerative diseases outweighs the current financial risks for investors with a higher risk tolerance, assuming successful capital raises.

Keywords

Neurodegenerative Diseases, ALS, Multiple Sclerosis, Parkinson's Disease, Nanotechnology, CSN Therapeutics, CNM-Au8, Clinical Trials, FDA Approval, Biomarkers, NfL, GFAP, Drug Development, Biopharmaceutical, Orphan Drug, Going Concern, Capital Raise, Intellectual Property, Nasdaq